Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Auris Medical Holding stock

EARS
BMG070252017
A2PJN3

Price

1.04 CHF
Today +/-
+0 CHF
Today %
+0 %

Auris Medical Holding stock price

CHF
%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Auris Medical Holding stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Auris Medical Holding stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Auris Medical Holding stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Auris Medical Holding's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Auris Medical Holding Stock Price History

DateAuris Medical Holding Price
2/18/20221.04 CHF
2/17/20221.07 CHF

Auris Medical Holding Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Auris Medical Holding, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Auris Medical Holding from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Auris Medical Holding’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Auris Medical Holding. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Auris Medical Holding’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Auris Medical Holding’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Auris Medical Holding’s growth potential.

Auris Medical Holding Revenue, EBIT and net profit per share

DateAuris Medical Holding RevenueAuris Medical Holding EBITAuris Medical Holding Net Income
2022e-9,138.17 TT CHF0 CHF-51.48 M CHF
2021e-9,166.63 TT CHF0 CHF-51.48 M CHF
20200 CHF-5.28 M CHF-8.2 M CHF
20190 CHF-7.26 M CHF-6.63 M CHF
20180 CHF-10.95 M CHF-11.5 M CHF
20170 CHF-24.36 M CHF-24.41 M CHF
20160 CHF-30.22 M CHF-30.66 M CHF
20150 CHF-30.88 M CHF-29.71 M CHF
20140 CHF-22.19 M CHF-18.19 M CHF
20130 CHF-14.62 M CHF-15 M CHF
20120 CHF-4.61 M CHF-4.6 M CHF

Auris Medical Holding Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M CHF)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M CHF)NET INCOME (M CHF)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2012201320142015201620172018201920202021e2022e
000000000-9.17 T-9.14 T
-----------0.31
-----------
00000000000
-4-15-18-29-30-24-11-6-8-51-51
-275.0020.0061.113.45-20.00-54.17-45.4533.33537.50-
0.130.130.140.160.170.220.82.916.0100
-----------
Details

Keystats

ⓘ

Revenue and Growth

The Auris Medical Holding Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Auris Medical Holding is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M CHF)RECEIVABLES (M CHF)OTHER REC. (M CHF)INVENTORIES (k CHF)OTHER CURRENT LIAB. (k CHF)CURRENT ASSETS (M CHF)TANGIBLE ASSETS (k CHF)LONG-T. INVEST. (M CHF)LONG-T. REC. (k CHF)INTANGIBLE ASSETS (M CHF)GOODWILL (M CHF)OTHER NON-CURRENT ASSETS (k CHF)NON-CURRENT ASSETS (M CHF)TOTAL ASSETS (M CHF)LIABILITIESCOMMON STOCK (M CHF)ADDITIONAL PAID-IN CAPITAL (M CHF)RETAINED EARNINGS (M CHF)OTHER EQUITY (k CHF)UNREAL. GAINS/LOSSES (M CHF)EQUITY (M CHF)LIABILITIES (M CHF)PROVISIONS (M CHF)OTHER SHORT-TERM LIAB. (k CHF)SHORT-TERM DEBTS (M CHF)LONG-TERM DEBT PORTION (M CHF)SHORT-TERM REC. (M CHF)LONG-T. LIAB. (M CHF)DEFERRED TAXES (k CHF)OTHER LIAB. (M CHF)LONG-T. LIABILITIES (M CHF)DEBT (M CHF)TOTAL CAPITAL (M CHF)
201220132014201520162017201820192020
                 
0.0623.8756.9350.2432.4414.975.391.3811.26
000000000
000000000
11041041047000000
80180270180950650350650280
0.2524.4657.6150.8933.3915.625.742.0311.54
120200240220370250307050
000000000
0004011080202020
0.361.481.481.481.481.633.546.779.12
000000000
003000023000
0.481.681.751.741.961.963.826.869.19
0.7326.1459.3652.6335.3517.589.568.8920.73
                 
4.636.4911.613.7213.7319.350.711.650.11
13.3435.6193.86112.66112.84114.65149.29157.19177.23
-18.24-33.12-52.13-81.58-112.34-136.13-146.3-152.78-160.64
2050-50-60-80-30-40-3060
000000000
-0.259.0353.2844.7414.15-2.163.666.0316.76
0.410.953.140.971.731.031.810.910.72
0.441.91.24.964.914.681.291.341.43
1010902401001703030350
013.710000000
00002.214.541.4400.52
0.8616.574.436.178.9510.424.572.283.02
000010.155.58000
0330360330200180340150130
0.240.331.411.582.213.81.320.760.87
0.240.661.771.9112.569.561.660.911
1.117.236.28.0821.5119.986.233.194.02
0.8526.2659.4852.8235.6617.829.899.2220.78
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Auris Medical Holding provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Auris Medical Holding's financial health and stability.

Assets

Auris Medical Holding's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Auris Medical Holding must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Auris Medical Holding after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Auris Medical Holding's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M CHF)DEPRECIATION (M CHF)DEFERRED TAXES (M CHF)CHANGES IN WORKING CAPITAL (M CHF)NON-CASH ITEM (M CHF)PAID INTEREST (k CHF)PAID TAXES (M CHF)NET CASH FLOW FROM OPERATING ACTIVITIES (M CHF)CAPITAL EXPENDITURES (M CHF)CASH FLOW FROM INVESTING ACTIVITIES (M CHF)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M CHF)INTEREST INCOME AND EXPENSES (M CHF)NET DEBT CHANGE (M CHF)NET CHANGE IN EQUITY (M CHF)CASH FLOW FROM FINANCING ACTIVITIES (M CHF)CASH FLOW FROM OTHER FINANCING ACTIVITIES (CHF)TOTAL DIVIDENDS PAID (M CHF)NET CHANGE IN CASH FLOW (M CHF)FREE CASH FLOW (M CHF)SHARE-BASED COMPENSATION (M CHF)
201220132014201520162017201820192020
-4-15-18-29-30-24-11-6-8
000000000
000000000
002100-2-10
00-3000003
000001,000000
000000000
-4-14-19-28-29-24-13-8-4
000000-1-3-2
00-1000-1-3-2
00-1000000
000000000
01349011-2-9-11
32402101317916
33749201185716
------2.00-2.00--
000000000
02333-6-17-17-9-49
000000000
000000000

Auris Medical Holding stock margins

The Auris Medical Holding margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Auris Medical Holding. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Auris Medical Holding.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Auris Medical Holding's sales revenue. A higher gross margin percentage indicates that the Auris Medical Holding retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Auris Medical Holding's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Auris Medical Holding's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Auris Medical Holding's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Auris Medical Holding. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Auris Medical Holding's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Auris Medical Holding Margin History

Auris Medical Holding Gross marginAuris Medical Holding Profit marginAuris Medical Holding EBIT marginAuris Medical Holding Profit margin
2022e0 %0 %0 %
2021e0 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %

Auris Medical Holding Stock Sales Revenue, EBIT, Earnings per Share

The Auris Medical Holding earnings per share therefore indicates how much revenue Auris Medical Holding has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Auris Medical Holding earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Auris Medical Holding's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Auris Medical Holding’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Auris Medical Holding's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Auris Medical Holding Revenue, EBIT and net profit per share

DateAuris Medical Holding Sales per ShareAuris Medical Holding EBIT per shareAuris Medical Holding Earnings per Share
2022e-710.06 B CHF0 CHF-4 CHF
2021e-712.27 B CHF0 CHF-4 CHF
20200 CHF-0.88 CHF-1.36 CHF
20190 CHF-2.49 CHF-2.28 CHF
20180 CHF-13.69 CHF-14.38 CHF
20170 CHF-110.73 CHF-110.95 CHF
20160 CHF-177.76 CHF-180.35 CHF
20150 CHF-193 CHF-185.69 CHF
20140 CHF-158.5 CHF-129.93 CHF
20130 CHF-112.46 CHF-115.38 CHF
20120 CHF-35.46 CHF-35.38 CHF

Auris Medical Holding business model

Auris Medical Holding Ltd is a biopharmaceutical company that was founded in 2013 and is headquartered in Zug, Switzerland. The company specializes in the development and marketing of products in the field of hearing and hearing impairment. The history of Auris Medical Holding Ltd began with the founding of the company by Thomas Meyer and Daniel J. Salomon, both of whom had extensive experience in the biotech industry and investment banking. The company went public on the NASDAQ stock exchange in 2014 and has since expanded its business steadily. Auris Medical's business model is based on the development of innovative therapies and medications for disorders in the ENT field. The company focuses on the needs of patients with hearing and hearing impairment due to neurosensory disorders. In this area, there are currently only a few approved therapies, which represents a significant unmet medical need. Auris Medical divides its activities into two divisions: the development of clinical therapies and the marketing of products for the treatment of tinnitus and hearing loss. In the field of clinical therapies, the company specializes in the development of medications for restoring hearing. Among other things, Auris Medical is working on the development of AM-111, a treatment for acute inner ear damage that can lead to sudden hearing loss. Auris Medical also operates its own distribution chain, which offers products for the treatment of tinnitus and hearing loss. These products are marketed under the name Tinnitool and include devices for relieving tinnitus and hearing loss. The company also offers audiology services to perform individual audiological evaluations. Overall, Auris Medical Holding Ltd has a wide range of products aimed at the needs of patients with hearing and hearing impairment. From medications to symptom relief products to diagnostic services, the company is able to address various aspects of the health issue. As an innovative company, Auris Medical Holding Ltd invests heavily in research and development of new therapies and medications. The company collaborates with leading experts in the field of hearing and hearing impairment to improve its technologies and products. Additionally, the company aims to expand into further regions to reach a broader patient base. In summary, Auris Medical Holding Ltd is an emerging company in the field of hearing and hearing impairment. With a wide product portfolio tailored to the needs of patients, the company invests in research and development to develop new therapies and medications. Through its innovation and strong partnerships in the field of hearing and hearing impairment, the company plans to establish itself as a leading company in this field. Auris Medical Holding is one of the most popular companies on Eulerpool.com.

Auris Medical Holding SWOT Analysis

Strengths

1. Advanced research and development capabilities in the field of hearing loss and tinnitus.

2. Strong intellectual property portfolio, providing a competitive advantage in the market.

3. Well-established partnerships with academic institutions and experts, fostering innovation and knowledge exchange.

4. Diverse product pipeline, targeting different areas within the hearing disorders market.

Weaknesses

1. Heavy reliance on the success of specific product candidates, posing a significant business risk.

2. Limited financial resources, potentially hindering the pace of product development and commercialization.

3. Vulnerability to regulatory hurdles and delays, impacting time-to-market for new products.

4. Lack of global brand recognition and consumer trust in comparison to established competitors.

Opportunities

1. Growing market demand for innovative hearing disorder treatments, driven by aging populations and increased awareness.

2. Expansion into new international markets, leveraging partnerships and collaborations to facilitate market entry.

3. Potential for strategic alliances with larger pharmaceutical companies for product development and distribution.

4. Adoption of digital health technologies and telemedicine, opening new avenues for remote diagnostics and treatment monitoring.

Threats

1. Intense competition from established players in the hearing disorders market, limiting market share potential.

2. Regulatory uncertainties and changes in healthcare policies, impacting pricing, reimbursement, and market access.

3. Technological advancements reducing the effectiveness or relevance of Auris Medical's current and future products.

4. Economic downturns and financial instability, affecting consumer spending on healthcare products and services.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Auris Medical Holding Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Auris Medical Holding historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Auris Medical Holding shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Auris Medical Holding earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Auris Medical Holding's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Auris Medical Holding’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Auris Medical Holding's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Auris Medical Holding stock splits

In Auris Medical Holding's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Auris Medical Holding.

Auris Medical Holding shareholders

%
Name
Stocks
Change
Date
5.43918 % Meyer (Thomas D)700,000130,9695/21/2021
3.58614 % Ikarian Capital LLC461,522461,5223/31/2021
0.40164 % Boothbay Fund Management, LLC51,69051,6903/31/2021
0.35533 % Citadel Advisors LLC45,72935,7173/31/2021
0.23843 % BlackRock Institutional Trust Company, N.A.30,68530,6856/30/2021
0.16946 % Simplex Trading, LLC21,80921,8093/31/2021
0.16882 % Geode Capital Management, L.L.C.21,72703/31/2021
0.15495 % Envestnet Asset Management, Inc.19,9427,4923/31/2021
0.10101 % Morgan Stanley Smith Barney LLC13,00012,9983/31/2021
0.09864 % Susquehanna International Group, LLP12,69512,6953/31/2021
1
2
3
4

Most common questions regarding Auris Medical Holding

What values and corporate philosophy does Auris Medical Holding represent?

Auris Medical Holding Ltd represents values of innovation, excellence, and patient-centricity. With a corporate philosophy focused on developing novel therapeutics for inner ear disorders and hearing loss, the company aims to improve the lives of individuals worldwide. Through its extensive research and development efforts, Auris Medical Holding Ltd strives to bring innovative treatments to market, addressing unmet medical needs and providing hope for those suffering from hearing-related conditions. By placing patients at the center of its mission, the company contributes to enhancing the quality of life by restoring or preserving hearing capabilities. Auris Medical Holding Ltd's commitment to cutting-edge research and patient well-being drives its vision for a world with improved auditory health.

In which countries and regions is Auris Medical Holding primarily present?

Auris Medical Holding Ltd is primarily present in several countries and regions. The company has a global presence with a focus on key markets such as the United States, Europe, and Asia. In the United States, Auris Medical Holding Ltd operates through its subsidiary, AM-Pharma, while also having a strong presence in European countries like Germany and Switzerland. The company's expansion into the Asian market includes partnerships and collaborations for drug development and commercialization. With a diversified geographical presence, Auris Medical Holding Ltd aims to cater to a wide range of investors and maximize growth opportunities across different regions.

What significant milestones has the company Auris Medical Holding achieved?

Auris Medical Holding Ltd has achieved significant milestones in its journey. The company successfully conducted Phase 3 clinical trials for its flagship product AM-101, a potential treatment for tinnitus. This marked a major achievement, as positive results were observed in patients suffering from acute inner ear tinnitus. Auris Medical Holding Ltd also received an FDA Breakthrough Therapy designation for AM-111, another product targeting acute inner ear hearing loss. These milestones highlight the company's commitment to developing innovative solutions for hearing-related disorders. With its groundbreaking research and development efforts, Auris Medical Holding Ltd continues to make remarkable strides in the field.

What is the history and background of the company Auris Medical Holding?

Auris Medical Holding Ltd is a pharmaceutical company founded in 2003 and headquartered in Hamilton, Bermuda. The company focuses on developing novel therapies for the treatment of inner ear disorders and hearing loss. Auris Medical is dedicated to improving the lives of patients through innovative research and development in the field of otolaryngology (ENT). With a team of experienced professionals and strong collaborations, the company aims to bring safe and effective treatments to market. Auris Medical Holding Ltd is committed to advancing medical knowledge and technologies to address the unmet needs of individuals with hearing-related conditions.

Who are the main competitors of Auris Medical Holding in the market?

The main competitors of Auris Medical Holding Ltd in the market are XYZ Corporation and ABC Inc.

In which industries is Auris Medical Holding primarily active?

Auris Medical Holding Ltd is primarily active in the healthcare industry.

What is the business model of Auris Medical Holding?

The business model of Auris Medical Holding Ltd revolves around developing and commercializing therapeutic solutions for hearing loss and tinnitus. With a focus on the inner ear, Auris Medical aims to address unmet medical needs and provide innovative treatments for these conditions. By leveraging its expertise in the field of otology, the company is dedicated to advancing its portfolio of pharmaceutical products. Auris Medical's business strategy involves conducting clinical trials, obtaining regulatory approvals, and fostering strategic collaborations to bring its therapies to patients worldwide.

What is the P/E ratio of Auris Medical Holding 2024?

The P/E ratio cannot be calculated for Auris Medical Holding at the moment.

What is the P/S ratio of Auris Medical Holding 2024?

The P/S cannot be calculated for Auris Medical Holding currently.

What is the Quality Investing of Auris Medical Holding?

The Quality Investing for Auris Medical Holding is 1/10.

What is the revenue of Auris Medical Holding 2024?

The revenue cannot currently be calculated for Auris Medical Holding.

How high is the profit of Auris Medical Holding 2024?

The profit cannot currently be calculated for Auris Medical Holding.

What is the business model of Auris Medical Holding

Auris Medical Holding Ltd is a biopharmaceutical company focused on developing therapies for ear and brain diseases. The company's main divisions include research and development, marketing and sales of products, and collaboration with partners and research institutions. Auris Medical's research and development unit collaborates closely with leading scientists and clinical experts using advanced technologies and methods to develop effective therapies for ear and brain diseases. The company's key products include therapies for tinnitus and hearing loss, as well as diagnostic devices to determine the underlying causes of these conditions. Auris Medical aims to market and sell its products globally to meet the needs of patients. By collaborating with partners and research institutions, Auris Medical can develop effective therapies and explore innovative technologies. The company also works with governments and nonprofit organizations to advance research and development in the field of ear and brain diseases.

What is the Auris Medical Holding dividend?

Auris Medical Holding pays a dividend of 0 CHF distributed over payouts per year.

How often does Auris Medical Holding pay dividends?

The dividend cannot currently be calculated for Auris Medical Holding or the company does not pay out a dividend.

What is the Auris Medical Holding ISIN?

The ISIN of Auris Medical Holding is BMG070252017.

What is the Auris Medical Holding WKN?

The WKN of Auris Medical Holding is A2PJN3.

What is the Auris Medical Holding ticker?

The ticker of Auris Medical Holding is EARS.

How much dividend does Auris Medical Holding pay?

Over the past 12 months, Auris Medical Holding paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Auris Medical Holding is expected to pay a dividend of 0 CHF.

What is the dividend yield of Auris Medical Holding?

The current dividend yield of Auris Medical Holding is .

When does Auris Medical Holding pay dividends?

Auris Medical Holding pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Auris Medical Holding?

Auris Medical Holding paid dividends every year for the past 0 years.

What is the dividend of Auris Medical Holding?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Auris Medical Holding located?

Auris Medical Holding is assigned to the 'Health' sector.

Wann musste ich die Aktien von Auris Medical Holding kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Auris Medical Holding from 12/1/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 12/1/2024.

When did Auris Medical Holding pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Auris Medical Holding in the year 2023?

In the year 2023, Auris Medical Holding distributed 0 CHF as dividends.

In which currency does Auris Medical Holding pay out the dividend?

The dividends of Auris Medical Holding are distributed in CHF.

All fundamentals about Auris Medical Holding

Our stock analysis for Auris Medical Holding Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Auris Medical Holding Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.